poisar

Stocks · News reference

HC Wainwright & Co. Maintains Buy on Intensity Therapeutics, Raises Price Target to $7

BenzingaBenzinga Newsdesk

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. BenzingaBenzinga Newsdesk

    Intensity Therapeutics Q2 EPS $(1.11), Inline

    Intensity Therapeutics (NASDAQ:INTS) reported quarterly losses of $(1.11) per share which met the analyst consensus estimate. This is a 66.96 percent increase over losses of $(3.36) per share from the same period last